Close menu




October 15th, 2020 | 13:16 CEST

Bayer, Triumph Gold, BioNTech - decisive phase!

  • Investments
Photo credits: pixabay.com

Almost everyone knows the philosophies proclaimed by the great and wise stock market gurus. “Never try catch a falling knife" or "buy on the sound of cannons, sell on the sound of trumpets”. What is true? In the case of Bayer, after the Monsanto disaster, possibly higher than planned fines and a cracking profit warning, one might think that everything has already been priced in. However, it is still not known how and when the Monsanto disaster will end. The fact is, there are other, more appealing papers at the moment ...

time to read: 2 minutes | Author: Stefan Feulner
ISIN: CA8968121043 , DE000BAY0017 , US09075V1026

Table of contents:


    Trust from Switzerland

    Despite a stable market environment, Bayer continued to move south. Dropping below the EUR 45.00 mark marked a 5-year low. The Leverkusen-based Company was encouraged by the Swiss, of all countries. The major Swiss bank UBS left the rating for Bayer at "Buy" with a price target of EUR 85.00. Despite the announced dividend cut, UBS does not necessarily see Bayer as lacking money. The analyst cites as the reason that the pharmaceutical giant only issued a bond with a volume of EUR 6 billion in August.

    Besides, it would also be possible to generate cash by selling shares. Given the profit warning that was issued shortly before the issuing of the bond and the continuing uncertainty about possible fines, caution is still necessary at the current level.

    Before all-time high

    Everything else how bad things are going at the moment for the Mainz-based developer of a vaccine against the pandemic pathogen. The exploding COVID-19 infection figures are another reason why the Company is on everyone's lips.

    The vaccine candidate BNT162, developed in cooperation with Pfizer, is currently being tested in final clinical trials. About 37,000 participants in the study have already received vaccinations, 28,000 have received two doses. There are 120 sites worldwide involved in this clinical study.

    From a chartist's point of view, the upward trend, which has been in evidence since October 2019 and currently stands at EUR 55.00, is fully intact. If the positive news continues in the coming weeks, it is only a matter of time before the EUR 100.00 mark is reached and broken through.

    Opportunity after consolidation

    The stock of the Canadian gold explorer Triumph Gold also corrected sharply. In August 2020, the share price was at CAD 0.48, but now almost half of it is at CAD 0.25. The reasons for the fall to the south are, on the one hand, the weakening gold price and, of course, the still too weak sales due to the Company's high profile, this of course results in increased volatility, but also a great opportunity.

    Triumph Gold Corp. is a growth-oriented Canadian gold exploration and development company with a large land package in the mining-friendly Yukon. The Company's flagship project, Freegold Mountain, is located in the Dawson Range. It hosts three NI 43-101 compliant mineral deposits. It covers an extensive area of the Big Creek Fault Zone, a structure similar to epithermal gold and silver mineralization, and gold-rich porphyry copper mineralization.

    Successful Exploration Program

    As of September 18, 2020, Triumph Gold announced that it had completed the fully funded exploration program PR20-07. The program included minor trenching and reconnaissance sampling, as well as 2,068 meters of diamond drilling. The partially near-surface surveys are now in the evaluation and analysis phase. According to Jesse Halle, Vice President of Exploration, several of the reconnaissance samples collected indicate that gold mineralization is much more widespread than previously thought. As a result, the 2021 exploration program is to expand.

    Also noteworthy is the Canadian shareholder list, which includes known names. In addition to the Zijn Mining Fund, industry leader Newmont Mining is also a shareholder.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read